SGEN - Seattle Genetics, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Seattle Genetics, Inc.

21823 30th Drive SE
Bothell, WA 98021
United States
425 527 4000

Full-time employees1,605

Key executives

NameTitlePayExercisedYear born
Dr. Clay B. SiegallCo-Founder, Chairman, Pres & CEO2.88M19.58M1961
Mr. Todd E. SimpsonChief Financial Officer1.11MN/A1961
Ms. Jean I. LiuGen. Counsel, Exec. VP of Legal Affairs & Corp. Sec.1MN/A1968
Dr. Roger D. Dansey M.D.Chief Medical Officer1.74M535.65k1957
Dr. Vaughn B. HimesChief Technology OfficerN/AN/A1961
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seattle Genetics, Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and biotechnology and pharmaceutical companies. Seattle Genetics, Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Corporate governance

Seattle Genetics, Inc.’s ISS governance QualityScore as of 5 December 2019 is 4. The pillar scores are Audit: 2; Board: 5; Shareholder rights: 5; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more